Twist Bioscience Corporation TWST Issuance of common stock for the acquisition of Ansys

Issuance of common stock for the acquisition of Ansys at other companies

10x Genomics, Inc.TXG

——

Apogee Therapeutics, Inc.APGE

——

Other financials

Income statement

See full

Revenue$110.7M+19.3%

Gross profit$57.1M+24.1%

Operating income-$45.9M-10.4%

Net income-$44.0M-11.9%

EPS (diluted)-$0.71-7.6%

Balance sheet

See full

Cash & equivalents$124.9M-41.4%

Total debt$110.8M+16.3%

Total equity$455.1M+3.4%

Total assets$676.2M+13.5%

Cash flow

See full

Operating cash flow-$17.6M-35.2%

CapEx$7.9M+90.3%

Free cash flow-$25.4M-48.5%

Valuation

See full

Market cap$5.45B+24.4%

Enterprise value$5.44B+30.4%

P/S13.3×+0.7×

Profitability

See full

Gross margin52.1%+5.4pp

Operating margin-33.9%-9.9pp

Net margin-19.8%-7.7pp

FCF margin-23.2%+7.0pp

Returns & leverage

See full

Return on equity-18.2%-6.3pp

Debt / equity0.2×0.0×

Current ratio2.7×-1.8×

Where this comes from

Reported directly by Twist Bioscience Corporation in its filing.

Tagged under the XBRL concept us-gaap:StockIssued1.

The official record: Twist Bioscience Corporation’s 10-K, filed November 17, 2025, on SEC EDGAR. View the filing →

Ask your AI about Twist Bioscience Corporation's issuance of common stock for the acquisition of ansys.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Twist Bioscience Corporation's issuance of common stock for the acquisition of ansys?: Twist Bioscience Corporation (TWST) reported issuance of common stock for the acquisition of ansys of $0 in Q3 2025.
What is the long-term trend for Twist Bioscience Corporation's issuance of common stock for the acquisition of ansys?: Over 2 years (2021 to 2025), Twist Bioscience Corporation's issuance of common stock for the acquisition of ansys has grown at a -100.0% compound annual growth rate (CAGR), from $26.77M to $0.